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1. Introduction 
The neurointermediate lobe of the African clawed 
frog Xenopus laevis synthesizes a common precursor 
to adrenocorticotropin (ACTH) and P-lipotropin (PLPH), 
which is also processed to a-melanocyte stimulating 
hormone (oMSH) and P-endorphin, the opiate-like 
peptide ([l] , Y.P.L., in preparation). This precursor is 
a glycoprotein with an RF of 0.46 (relative to cyto- 
chrome c) on acid-urea gels and mol. wt 32 000 on 
sodium dodecyl sulfate (SDS)-gels (Y.P.L., H.G., in 
preparation), and appears to be similar to that 
reported for the AtT-20 mouse pituitary tumor line 
[2-41. Beeley [S] has proposed that the addition of 
carbohydrates at the p-turns of proteins would result 
in the masking of the turn conformations, and hence, 
could be an important feature in protecting the mole- 
cule from proteolysis. Glycosylation of secretory 
proteins has also been suggested to be a prerequisite 
for secretion, e.g., for thyroglobulin [6,7]. We have 
therefore examined the role of the carbohydrate on 
the ACTH-/?LPH hormone precursor with respect to 
these two issues, using the drug, tunicamycin, an 
inhibitor of glycosylation. In this short communica- 
tion, we present data in support of the hypothesis 
[5] showing that the lack of glycosylation of the 
ACTH-PLPH common precursor resulted in its rapid 
degradation, and formation of atypical processed 
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peptides. The secretion of the processed peptides 
appeared to be unaffected by tunicamycin. 
2. Materials and methods 
2.1. Animals 
Adult African clawed frogs (Xenopus laevis) 
40-70 g, were purchased from NASCO Biological 
Supplies, Fort Atkinson, WI and maintained in a 
black plastic aquarium at 22’C with 12 h dark-light 
cycles, for 15-20 days before use. This dark adapta- 
tion was to enhance the synthesis of ACTH and 
MSH in the neurointermediate lobe [l] . 
2.2. Incubation of neurointennediate lobes in radio- 
active arginine 
Neurointermediate lobes of the pituitary were 
dissected from the animals and preincubated at 
22°C in amphibian ringer (NaCl 112 mM, KC1 
2 mM, CaC12 2 mM, Hepes 15 mM, glucose 5 mg/ml; 
bovine serum albumin 1 mg/ml, ascorbic acid 1 mg/l, 
pH 7.35) for 6 h and then ‘pulse’ incubated for 
30 min in amphibian ringer containing 17.5 E.~M 
[3H]arginine, (New England Nuclear, Boston, MA; 
spec. act. = 28.5 Ci/mmol). After the pulse, the 
labeled lobes were either chased in amphibian ringer 
with 1 mM unlabeled arginine, for varying times and/ 
or homogenized in O.lN HCl. The chase medium was 
collected and HCl added to 0.1 N final cont. Proteins 
in the tissue homogenates and medium were then pre- 
ElsevierfNorth-Holland Biomedical Press 269 
Volume 96, number 2 FEBS LETTERS December 1978 
cipitated with cold 10% trichloroacetic acid (TCA) 
and the TCA precipitates analysed by acid-urea gel 
electrophoresis in [8,9] . 
2.3, Treatment of the neurointermediate lobes with 
tunicamycitz 
Neurointermediate lobes were preincubated for 
6 h (minimum time for maximal effect of tuni- 
camycin), pulse incubated, and chased as above 
except that 5 pg/ml of tunicamycin (a generous gift 
from Dr G. Tamura, Univ. Tokyo) was included 
throughout the procedure. Tunicamycin inhibits 
glycosylation of proteins by specifically inhibiting 
the synthesis of those sugar side chains which have 
N-acetylglucosamine linked to aspargine residues of 
glycoproteins, by preventing the formation of N- 
acetylglucosaminyl-dolichol phosphate intermediates 
[IO-121 . Control experimentsmeasuring [jH]arginine 
and [3H]glucosamine incorporation show that with 
tunicamycin treatment, the common precursor to 
ACTH and &lipotropin (peak ‘a’ in fig. 1 A) was not 
inhibited in its synthesis, but was inhibited in its 
glycosylation by 93% + 2.8. Tissues treated with 
tunicamycin were homogenized and analysed by 
acid-urea gel electrophoresis as described above. 
3. Results 
Figure 1A shows the effect of tunicamycin on the 
synthesis of the ACTH-@LPH common precursor 
shown as peak ‘a’ on the control acid-urea gel profile 
(open circles). Synthesis of the precursor is compared 
in untreated (control, open circles) and tunicamycin 
treated lobes (closed circles), after a 30 min pulse 
labeling with [3H]arginine. The results suggest hat 
there is virtually no inhibition of precursor (peak ‘a’) 
synthesis after tunicamycin treatment except that the 
unglycosylated form migrated faster on the gel. The 
radioactivity in the unglycosylated peak ‘a’ was found 
to be 92.5% + 12 (n = 3) of control value. Since the 
acid-urea gel separates primarily on the basis of size, 
the faster mobility of peak ‘a’ with tunicamycin treat- 
ment is consistent with the expectation that the 
unglycosylated precursor has a lower molecular weight 
without the sugars attached. The unglycosylated peak 
‘a’ was otherwise indistinguishable from the normally 
glycosylated peak ‘a’ with respect o immunoreactivity 
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with ACTH and fl endorphin antisera (Y.P.L., H.G., in 
preparation). 
After a 30 min pulse followed by a 1 h chase. 
(fig. 1 B, open circles) the precursor peak ‘a’ underwent 
processing to 3 forms of immunoreactive ACTH: two 
glycoproteins (peak ‘c’, RF 0.65, mol. wt 21 000, and 
peak ‘e’, RF 0.83, mol. wt 13 000) and peptide peak 
‘i’ (RTT 1.3. mol. wt 4300) which coran with 
ACTHl_,9. Two other peptides. immunoreactive 
oMSH (peak ‘j’) and immunoreactive &PH (peak ‘8’) 
were also processed from the precursor (Y.P.L., in 
preparation). While in the control lobes (fig. 1 B, open 
circles) there was a considerable amount of peak ‘a’, 
after 1 h chase, in the tunicamycin-treated lobes. 
there was a significant disappearance of peak ‘a’ 
without the conservation of radioactivity in the tissue 
in the form of processed product peaks (fig. 1 B. closed 
circles). However, some processing of the precursor 
which appeared to escape degradation did occur, 
yielding a peak which migrated slightly faster than 
peak ‘c’ in acid-urea gels, but the presence of other 
processed products (peaks ‘e’, ‘g’. ‘i’ and ‘j’) were not 
detected. The major processed product in the tuni- 
camycin treated lobes, i.e., the peak that migrated 
ahead of peak ‘c’ in the control profile (open circles) 
may represent an unglycosylated form of peak ‘c’. 
Figure 1C (open circles) shows the peptides 
normally released by the neurointermediate lobe. The 
3 forms of immunoreactive ACTH (peaks ‘c’. ‘e’ and 
‘i’) as well as aMSH (peak ‘j’) and /3LPH (peak ‘8’) 
were released. In the presence of tunicamycin, 
atypical peptides (a presumed unglycosylated peak 
‘c’ and a peak comigrating with peak ‘g’ in the control 
lobes), appear to be released (fig.lC, closed circles). 
Peaks ‘kr’, ‘ k2’ and ‘1’ (fig.lB,lC, open circles) are 
other large glycoproteins synthesized and released by 
the neurointermediate lobe and are not related to the 
processing of the common precursor peak ‘a’ (Y.P.L., 
H.G., in preparation). Note also in the release profile 
(fig. 1C) the difference in ratio of peak ‘c’ relative to 
peaks ‘kr’, ‘kz’ and ‘1’ in the control (open circles) and 
tunicamycin treated lobes (closed circles) suggesting 
the instability of the presumed unglycosylated form 
ofpeak ‘c’. We have shown that the release of peptides 
is normally under inhibitory control by dopamine 
[I] . The pathway of release of the atypical peptides 
in tunicamycin treated lobes (seen in fig. 1 C) is also 
inhibited by dopamine (data not shown). Thus, it 
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35or appears that the lack of glycosylation of precursor 
has no effect on the secretion mechanism per se. 
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4. Discussion 
Using the drug tunicamycin, which inhibits the 
lipid-linked pathway for the core glycosylation of 
glycoproteins [ 10-121, it was shown that the bio- 
synthesis of the unglycosylated common precursor 
to ACTH and /3LPH was not inhibited (fig.lA). How- 
ever, during the chase period, it was found that there 
was an enhanced proteolysis of the unglycosylated 
precursor in comparison to the normally glycosylated 
form in control tissue (fig. 1 B). Moreover, the 
unglycosylated precursor which did escape degrada- 
tion was processed to a set of atypical peptides which 
was secreted by the lobe (fig.lB,lC) via a dopamine- 
inhibited pathway similar to normal lobes. This data 
Fig.1. Acid-urea gel labeling profnes of TCA-precipitable 
peptides synthesized and released by neurointermediate lobes 
after pulse labeling in the presence and absence of tunicamycin. 
(A) Lobes were preincubated for 6 h in amphibian ringer with 
and without tunicamycin and then pulse labeled for 30 min 
in [3H]arginine * tunicamycin. (o----o) Without tunica- 
mycin (control); (o----o) with tunicamycin treatment. 
The ACTH-pLPH precursor is denoted by peak ‘a’. 
(B) Lobes were preincubated for 6 h in amphibian ringer 
(+ tunicamycin), pulse-labeled for 30 min in [3H]arginine 
(? tunicamycin) and then chased for 1 h (? tunicamycin). 
(o----o) Without tunicamyin (control), (e----o) with 
tunicamycin treatment. Peak ‘a’is the ACTH-0LPH precursor 
and peaks ‘c-g’, ‘i’ and ‘j’ are processed peptides. Peaks ‘c’, 
I 
‘e’ and ‘i’ are immunoreactive forms of ACTH, peak ‘g’ has 
been identified as pLPH and peak ‘J’ as aMSH (Y.P.L. in 
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preparation, see text). 
(C) Lobes were preincubated for 6 h in amphibian ringer 
(+ tunicamycin), pulse-labeled for 30 min in [“Hlarginine 
(+ tunicamycin) then chased for 3 h (t tunicamycin). The 
chase media were collected for analysis of secreted peptides. 
3 h was the optimum release time determined [ 11. (o----0) 
Without tunicamycin; (o----e) with tunicamycin treat- 
ment. The processed peptides peaks ‘c’, ‘e’, ‘g’, ‘i’ and ‘j’ are 
released in control lobes while the atypical peptides in 
300 
C 
v c 3h. Chose medium 
6 250 b4 Control 
8 - 2 Tunicamycin treated 
,200 
tunicamycin treated lobes are also released. In (A-C), the 
0 
0 
,o 20 30 40 50 60 70 ordinate shows the cpm/gel slice and the abscissa the slice 
SLICE NUMBER number. 
271 
Volume 96, number 2 FEBS LETTERS December 1978 
represents the first demonstration that the glycosyla- 
tion of a prohormone appears to be important for its 
protection from non-specific proteolysis, and provides 
experimental support for Beeley’s hypothesis [5]. 
Other studies have shown that when membrane 
proteins such as CSP (fibrinectin) and the hemag- 
glutinin precursor of influenza virus are prevented 
from glycosylation by tunicamycin, they are also 
increasingly degraded by intracellular proteases 
[13,14] . It is possible that the carbohydrate may also 
confer specific conformational properties to the 
ACTH-/ILPH precursor so as to direct programmed 
limited proteolysis (processing). 
The secretion of other glycoproteins CSP (fibri- 
nectin) and procollagen does not appear to be 
inhibited by tunicamycin [ 131 , consistent with the 
observations of this study. Thus contrary to previous 
proposals [6,7], glycosylation of secretory glyco- 
proteins is not a prerequisite for their secretion. 
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